No results found.
Timothy M. Fan, DVM, PhD, DACVIM (Oncology, Internal Medicine), University of Illinois
Sign in to Print/View PDF
This is a filled error message
To access full articles on www.cliniciansbrief.com, please sign in below.
Create an account for free
Want free access to the #1 publication for diagnostic and treatment information? Create a free account to read full articles and access web-exclusive content on cliniciansbrief.com.
Passwords do not match
Where are you from?
AG|Antigua and Barbuda
BA|Bosnia and Herzegowina
IO|British Indian Ocean Territory
CF|Central African Republic
CC|Cocos (Keeling) Islands
CD|Congo, the Democratic Republic of the
FK|Falkland Islands (Malvinas)
TF|French Southern Territories
HM|Heard and Mc Donald Islands
VA|Holy See (Vatican City State)
IR|Iran (Islamic Republic of)
KR|Korea, Republic of
LY|Libyan Arab Jamahiriya
MK|Macedonia, The Former Yugoslav Republic of
FM|Micronesia, Federated States of
MD|Moldova, Republic of
MP|Northern Mariana Islands
PG|Papua New Guinea
KN|Saint Kitts and Nevis
VC|Saint Vincent and the Grenadines
ST|Sao Tome and Principe
SK|Slovakia (Slovak Republic)
GS|South Georgia and the South Sandwich Islands
PM|St. Pierre and Miquelon
SJ|Svalbard and Jan Mayen Islands
SY|Syrian Arab Republic
TZ|Tanzania, United Republic of
TT|Trinidad and Tobago
TC|Turks and Caicos Islands
AE|United Arab Emirates
UM|United States Minor Outlying Islands
VG|Virgin Islands (British)
VI|Virgin Islands (U.S.)
WF|Wallis and Futuna Islands
DC|District of Columbia
Micronesia (Federated States Of)
US Minor Outlying Islands
Armed Forces Africa
Armed Forces Americas Aa (except Canada)
Armed Forces Canada
Armed Forces Europe Ae
Armed Forces Middle East Ae
Armed Forces Pacific Ap
PE|Prince Edward Island
Tell us about yourself
Choose the category that describes your business/professional activity
What best describes your position? (question 1 of 2)
Veterinarian Role: (question 2 of 2)
Non-Veterinarian Role: (question 2 of 2)
Yes, I would like to receive updates about products & services, promotions, special offers, news & events from Brief Media.
Already have an account? Sign in here.
Acceptance to the GDPR regulations is required.
Systemic chemotherapy remains a cornerstone for treating companion animals with cancer. The manner by which antineoplastic drugs are administered can be categorized in 2 therapeutic strategies: maximum-tolerated dose or metronomic chemotherapy (ie, low-dose daily oral administration).1,2 Oral cyclophosphamide, either alone or in conjunction with NSAIDs (eg, piroxicam), is the most common cytotoxic agent used for metronomic chemotherapy in veterinary patients.3,4 Although metronomic cyclophosphamide administration does not typically cause myelosuppression or GI toxicities, the metabolism of cyclophosphamide still results in production of acrolein, a potent uroepithelial irritant with the potential to cause sterile hemorrhagic cystitis (SHC).5 Strategies for mitigating the development of SHC involve reducing acrolein contact time with uroepithelial cells via drug-induced polyuria and administering furosemide or prednisolone.6
This retrospective study examined the incidence of clinically relevant SHC in pet dogs receiving long-term (>6 months) metronomic cyclophosphamide therapy with or without concurrent oral furosemide. Over a span of 6 years at a single institute, 115 dogs meeting study inclusion criteria were categorized into 2 groups and evaluated for the development of clinically relevant SHC. Among the dogs, 25 cases of SHC were either diagnostically confirmed (via urinalysis, urine culture, ultrasonography) or clinically suspected (unresponsiveness to antibiotic), amounting to an incidence of 21.7%. Significantly, the incidence of SHC was reduced in dogs treated with concurrent furosemide therapy (10.2% [5/49 dogs]) as compared with that in dogs not treated with furosemide (30.3% [20/66 dogs]). Collectively, these findings suggest that coadministration of furosemide along with long-term metronomic cyclophosphamide therapy can reduce the incidence of clinical signs associated with SHC.
Figure Visual (A) and chemical (B; ie, colorimetric) detection methods useful in complementing clinical signs (eg, hematuria, stranguria, pollakiuria) to support the presumed diagnosis of SHC. Visual assessments should be limited to detecting gross hematuria, whereas chemical detection (ie, urine dipstick) provides improved sensitivity for the identification of microscopic hematuria.
Key pearls to put into practice:
Oral metronomic cyclophosphamide therapy can result in uroepithelial irritation secondary to acrolein formation, even at low doses.
The overall incidence of SHC in pet dogs treated with metronomic cyclophosphamide is clinically relevant, with approximately 1 in 5 dogs being affected during long-term (>6 months) treatment.
Coadministration of furosemide (0.5-1.0 mg/kg q24h) with metronomic cyclophosphamide therapy can substantially reduce the likelihood of SHC-associated clinical signs (ie, hematuria, stranguria, pollakiuria).
Material from Clinician’s Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*
*2007-2017 PERQ and Essential Media Studies
It's Free & Simple
Delivered to Your Inbox
Join the Conversation
Follow us @CliniciansBrief
© 2018 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved.